SB 262 Requires health benefit plans to establish equal out-of-pocket requirements for oral anticancer medications and intravenously administered chemotherapy medications
Sponsor: Goodman
LR Number: 1411S.01I Fiscal Note: 1411-01N.ORG
Committee: Small Business, Insurance and Industry
Last Action: 3/29/2011 - Voted Do Pass S Small Business, Insurance and Industry Committee Journal Page:
Title: Calendar Position:
Effective Date: August 28, 2011

Full Bill Text | All Actions | Available Summaries | Senate Home Page | List of 2011 Senate Bills

Current Bill Summary


SB 262 - Under this act, any health benefit plan that provides coverage and benefits for cancer chemotherapy treatment shall not require a higher copayment, deductible, or coinsurance amount for a prescribed, orally administered anticancer medication that is used to kill or slow the growth of cancerous cells than what the plan requires for an intravenously administered or injected cancer medication that is provided, regardless of formulation or benefit category determination by the health carrier administering the health benefit plan. A health carrier shall not achieve compliance with the provisions of the act by imposing an increase in copayment, deductible, or coinsurance amount for an intravenously administered or injected cancer chemotherapy agent covered under the health benefit plan.

STEPHEN WITTE